Mohamed Sedky Mahmoud Sedky1,2, Hany Abdel Rahman3,4, Emad Moussa4,5, Hala Taha6,7, Tarek Raafat8, Omayma Hassanein9. 1. Department of Pediatrics, National Research Centre, Cairo, Egypt. mohamed.sedky@57357.com. 2. Department of Pediatric Oncology, Children Cancer Hospital, 1 Seket Al-Imam st., Al Sayyeda Zeinab, 26386, Cairo, Egypt. mohamed.sedky@57357.com. 3. Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt. 4. Children Cancer Hospital, Cairo, Egypt. 5. Department of Clinical Oncology, Menoufeya University, Cairo, Egypt. 6. Department of Pathology, Children Cancer Hospital, Cairo, Egypt. 7. National Cancer Institute, Cairo University, Cairo, Egypt. 8. Department of Radiology, National Cancer Institute, Cairo University, Children Cancer Hospital, Cairo, Egypt. 9. Department of Clinical Research, Children Cancer Hospital, Cairo, Egypt.
Abstract
OBJECTIVE: To report a single centre outcome of management of Langerhans cell histiocytosis (LCH), a clonal disease with involvement of various body systems. METHODS: Retrospective analysis of 80 pediatric LCH patients at Children Cancer Hospital-Egypt between July 2007 and December 2011 was performed. Patients were stratified and treated according to LCH III protocol. The median follow up period was 42 mo (range: 1.18 to 71 mo). RESULTS: At wk 6 and 12, 'better' response was obtained in 61 (76 %) and 74 (93 %) patients respectively. Afterwards, reactivation occurred in 25 patients (38 %), of them multiple episodes occurred in 5 patients (6.25 %), managed by repetition of 1st line treatment for once or more. The 5 y overall survival (OS) and event free survival (EFS) was 96.3 and 55 % respectively. At last follow up, better status was reached in 70 patients, 3 in each 'intermediate' and 'worse' status. Three high risk patients died and one patient was lost to follow up. CONCLUSIONS: In a single Egyptian pediatric LCH experience, the response to treatment is satisfactory and survival remains the rule except in high risk organs disease that still needs a new molecule for salvage. However in multiple reactivations, patients do well with repetition of the 1st line of treatment with or without methotrexate.
OBJECTIVE: To report a single centre outcome of management of Langerhans cell histiocytosis (LCH), a clonal disease with involvement of various body systems. METHODS: Retrospective analysis of 80 pediatric LCH patients at Children Cancer Hospital-Egypt between July 2007 and December 2011 was performed. Patients were stratified and treated according to LCH III protocol. The median follow up period was 42 mo (range: 1.18 to 71 mo). RESULTS: At wk 6 and 12, 'better' response was obtained in 61 (76 %) and 74 (93 %) patients respectively. Afterwards, reactivation occurred in 25 patients (38 %), of them multiple episodes occurred in 5 patients (6.25 %), managed by repetition of 1st line treatment for once or more. The 5 y overall survival (OS) and event free survival (EFS) was 96.3 and 55 % respectively. At last follow up, better status was reached in 70 patients, 3 in each 'intermediate' and 'worse' status. Three high risk patients died and one patient was lost to follow up. CONCLUSIONS: In a single Egyptian pediatric LCH experience, the response to treatment is satisfactory and survival remains the rule except in high risk organs disease that still needs a new molecule for salvage. However in multiple reactivations, patients do well with repetition of the 1st line of treatment with or without methotrexate.
Authors: Riccardo Haupt; Milen Minkov; Itziar Astigarraga; Eva Schäfer; Vasanta Nanduri; Rima Jubran; R Maarten Egeler; Gritta Janka; Dragan Micic; Carlos Rodriguez-Galindo; Stefaan Van Gool; Johannes Visser; Sheila Weitzman; Jean Donadieu Journal: Pediatr Blood Cancer Date: 2012-10-25 Impact factor: 3.167
Authors: G Tuysuz; I Yildiz; N Ozdemir; I Adaletli; S Kurugoglu; H Apak; S Dervisoglu; S Bozkurt; T Celkan Journal: Mediterr J Hematol Infect Dis Date: 2019-05-01 Impact factor: 2.576